Aurinia Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
AUPH$16.62+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
| As of December 31, | ||
|---|---|---|
| (in thousands) | 2023 | 2022 |
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and restricted cash | $48,875 | $94,172 |
| Short-term investments | 301,614 | 295,218 |
| Accounts receivable, net | 24,089 | 13,483 |
| Inventories, net | 39,705 | 24,752 |
| Prepaid expenses | 9,486 | 13,580 |
| Other current assets | 1,031 | 1,334 |
| Total current assets | 424,800 | 442,539 |
| Non-current assets: | ||
| Long-term investments | 201 | — |
| Other non-current assets | 1,517 | 13,339 |
| Property and equipment, net | 3,354 | 3,650 |
| Acquired intellectual property and other intangible assets, net | 4,977 | 6,425 |
| Finance right-of-use asset, net | 108,715 | — |
| Operating right-of-use assets, net | 4,498 | 4,907 |
| Total assets | $548,062 | $470,860 |
| LIABILITIES | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | 54,389 | 39,990 |
| Deferred revenue | 4,813 | 3,148 |
| Other current liabilities (of which $0.8 million in 2023 is due to a related party) | 2,388 | 2,033 |
| Finance lease liability | 14,609 | — |
| Operating lease liabilities | 989 | 936 |
| Total current liabilities | 77,188 | 46,107 |
| Non-current liabilities: | ||
| Finance lease liability | 75,479 | — |
| Operating lease liabilities | 6,530 | 7,152 |
| Deferred compensation and other non-current liabilities (of which $7.6 million in 2023 is due to a related party) | 10,911 | 12,166 |
| Total liabilities | 170,108 | 65,425 |
| Commitments and Contingencies (Note 13) | ||
| SHAREHOLDERS' EQUITY | ||
| Common shares - no par value, unlimited shares authorized, 143,833 and 142,268 shares issued and outstanding at December 31, 2023 and 2022, respectively | 1,200,218 | 1,185,309 |
| Additional paid-in capital | 120,788 | 85,489 |
| Accumulated other comprehensive loss | (730) | (1,061) |
| Accumulated deficit | (942,322) | (864,302) |
| Total shareholders' equity | 377,954 | 405,435 |
| Total liabilities and shareholders' equity | $548,062 | $470,860 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.